Elanco Animal Health (ELAN) – Riding a New Wave of Growth in Pet and Livestock Care
Elanco Animal Health has been one of 2025’s quiet success stories — up roughly 70% this year — but there are good reasons to think the move isn’t over yet. The stock trades around $22 and, according to JPMorgan, could still have more room to run, with the firm raising its price target to $24 and upgrading the stock to Overweight.
The story here is simple: Elanco is hitting its stride with a new generation of products that are already driving results. Its parasite protection treatment for dogs, Credelio Quattro, is performing ahead of expectations and beginning to make a meaningful contribution to revenue. Meanwhile, its livestock product Experior — which reduces ammonia emissions in cattle feed — is gaining traction as more producers adopt cleaner, more efficient practices.
JPMorgan also highlighted several new launches, including Zenrelia, Bovaer, and IL-31, that should accelerate revenue growth and improve margins over the coming years. Together, these products mark one of the strongest innovation cycles the company has seen in years — one that could carry well into 2026 and beyond.
Despite this year’s rally, Elanco still looks attractively valued relative to its growth outlook. For investors looking for exposure to the expanding animal health market — from pets to production — this could be a stock with more upside left in the tank.
